Director/PDMR Shareholding

Paris, France and Camberley, UK – 12 November 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 11 November 2020, Graham Mullis, Chief Executive of the Company, acquired 60,875 ordinary shares of €1/15 each in the Company at a price of £8.17 per share. The resultant beneficial shareholding of Mr Mullis is 122,506 ordinary shares representing 0.17% of the Company’s issued share capital.

https://novacyt.com/wp-content/uploads/2020/11/Novacyt-Directors-Dealings-RNS-Graham-Mullis-12.11.2020-ENGLISH.pdf